Intravitreal bevacizumab and cataract surgery after wet age-related macular degeneration
10.3969/j.issn.1672-5123.2010.07.003
- VernacularTitle:玻璃体腔内注射Bevacizumab联合白内障手术治疗湿性年龄相关性黄斑变性
- Author:
Ruiz-Moreno M JOSÉ
;
Montero A JAVIER
;
Amat-Peral, PEDRO
;
Lugo L FRANCISCO
- Publication Type:Journal Article
- Keywords:
age-related macular degeneration;
bevacizumab;
cataract surgery;
choroidal neovascularization
- From:
International Eye Science
2010;10(7):1245-1247
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To report the use of intravitreal bevacizumab associated with cataract surgery to prevent the re-activation of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).METHODS: Twelve eyes from 12 patients who had been previously treated for wet AMD and presented cataracts were operated on by clear cornea phacoemulsification with intraocular lens implantation, and an intravitreal injection of 1.25mg (0.05mL) bevacizumab was performed by the end of the procedure. The results were evaluated in terms of visual acuity improvement and reactivation of CNV, as determined by the appearance of fluid in optical coherence tomography (OCT). RESULTS: Best-corrected visual acuity(BCVA) significantly improved after surgery (P<0.01 and P=0.049 for BCVA after CNV closure and BCVA after cataract development respectively, Student's t test for paired data). Mean follow-up after cataract surgery was 11.8 months (SD 6.1, range 3 to 22 months). CNV reactivation or appearance of new CNV lesions was not observed in any case during follow-up. CONCLUSION: Intravitreal bevacizumab immediately after cataract surgery may prevent CNV reactivation in patients previously treated from CNV secondary to AMD.
